A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

97 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-04

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary objective

\- To determine the clinical prognosis by identifying the disease course and severity by treatment with or without eculizumab in patients with aHUS in Korea.

Secondary objectives

* To determine the clinical prognosis of the disease in all patients with aHUS in Korea.
* To determine the clinical prognosis of the disease in patients diagnosed with aHUS prior to the initiation of eculizumab reimbursement system in Korea.
* To determine the treatment responses by treatment options in patients with aHUS in Korea.
* To identify risk factors that affect mortality in all patients with aHUS in Korea.
* To investigate the recurrence and clinical prognosis in patients with aHUS in Korea when eculizumab is discontinued

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

NCT00844545

Atypical Hemolytic Uremic Syndrome

COMPLETED PHASE2

aHUS Observational Long Term Follow-Up

NCT01522170

Atypical Hemolytic Uremic Syndrome

TERMINATED

To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

NCT01755429

ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

COMPLETED

A Retrospective Non-Interventional Study to Evaluate the Impact of Eculizumab in Korean PNH Patients

NCT05337683

PNH

COMPLETED

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT01770951

Atypical Hemolytic Uremic Syndrome (aHUS)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As a retrospective, non-interventional, multi-center study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

aHUS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are clinically diagnosed with the aHUS

Exclusion Criteria

* Patients who are diagnosed with Shiga toxin-producing E. coli hemolytic-uremic syndrome (STEC-HUS).
* Patients with less than 10% in a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13) activity test

Eligible Sex

ALL

Accepts Healthy Volunteers

No